NCT03090035 is a Phase 3 clinical trial of Pegylated Interferon α2 in Hepatitis C, sponsored by Sheikh Zayed Medical College.

Who is sponsoring NCT03090035?

NCT03090035 is sponsored by Sheikh Zayed Medical College.

What drugs are being tested in NCT03090035?

Interventions in NCT03090035: Pegylated Interferon α2, Ribavirin.

What condition does NCT03090035 study?

NCT03090035 studies Hepatitis C, Hepatitis C Relapse.

Is NCT03090035 still recruiting?

NCT03090035 is currently completed. Last updated 25 April 2017.

Last reviewed 2017-04-25 · How we verify

NCT03090035

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

Completed Phase 3 Last updated 25 April 2017

What this trial tests

Phase 3 trial testing Pegylated Interferon α2 in Hepatitis C in 98 participants. Completed in 31 December 2014.

Timeline

1 January 2014

Primary endpoint
1 July 2014

31 December 2014

Quick facts

Lead sponsor	Sheikh Zayed Medical College
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	98
Start date	1 January 2014
Primary completion	1 July 2014
Estimated completion	31 December 2014
Sites	1 location across Pakistan

Drugs / interventions tested

Pegylated Interferon α2 — full drug profile →
Ribavirin — full drug profile →

Conditions studied

Hepatitis C — all drugs for Hepatitis C →
Hepatitis C Relapse — all drugs for Hepatitis C Relapse →

Sponsor

Sheikh Zayed Medical College

Who can join

Adults 20 to 80, any sex, with Hepatitis C or Hepatitis C Relapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: Pegulated Interferon α2 plus ribavirin is a treatment of choice in patients with chronic hepatitis C infection. This study was conducted to find out the frequency of different IL-28B (rs12979860) genotypes in patients with chronic hepatitis C (HCV genotype type 2 \& 3) infection treated with Pegulated Interferon α2 plus ribavirin and to evaluate the role of IL-28B genotypes in achieving Sustained Virological Response (SVR). Methods: In this non-randomized observational study, ninety eight (98) patients with diagnosis of chronic hepatitis C were included. In all patients, Peg-IFN plus Ribavirin were given in standard doses for 24 weeks. End treatment response, sustained virological response, and relapse rate were the primary endpoints of this study. Analysis of IL28B (rs12979860) polymorphism (CC, CT and TT) was performed by PCR-RFLP protocol.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interleukins in liver disease treatment.
Yang M, Zhang CY. · · 2024 · cited 8× · PMID 38495285 · DOI 10.4254/wjh.v16.i2.140

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Sheikh Zayed Medical College trials

Trials by the same sponsor.

NCT07374497 — Effect of Perineal Massage on the Frequency of Episiotomy and Perineal Tearing · NA · active not recruiting
NCT07349108 — Comparison of Manual Vacuum Aspiration and Dilatation and Curettage for Endometrial Sampling Adequacy in Women With Abno · NA · active not recruiting
NCT06809777 — Comparison Between Efficacy of Topical 25%Podophyllin and Cryotherapy on Genital Warts · Phase 2 · not yet recruiting
NCT07445282 — This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Me · Phase 4 · completed
NCT07535684 — Impact of Early Essential Newborn Care (EENC) on Maternal and Neonatal Outcomes in a Tertiary Care Hospital · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03090035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheikh Zayed Medical College
Last refreshed: 25 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03090035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing